ESH AL 2018 | FLT3 inhibitors in the treatment of AML

Name: FLT3 inhibitors in the treatment of AML
Uploaded: 2018-05-04T00:00:00.000Z
Duration: 1 min 12 s
Description: Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Farhad Ravandi • 4 May 2018

ESH AL 2018

Acute Myeloid Leukemia Leukemia Azacitidine Crenolanib Gilteritinib Midostaurin Quizartinib Sorafenib

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.